Advertisement

Topics

Protalex Awarded Grant from FDA Office of Orphan Products Development to Foster Clinical Development of PRTX-100 for the Treatment of Immune Thrombocytopenia

08:30 EDT 17 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded the Company a $403,000 grant to s...

Other Sources for this Article

LHA Investor Relations
Anne Marie Fields, 212-838-3777
afields@lhai.com

NEXT ARTICLE

More From BioPortfolio on "Protalex Awarded Grant from FDA Office of Orphan Products Development to Foster Clinical Development of PRTX-100 for the Treatment of Immune Thrombocytopenia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...